relief therapeutics swiss biopharmaceutical company based company focuses developing drugs serious diseases existing treatment options lead compound synthetic form natural peptide protects lung company incorporated relief therapeutics holdings ag rflbs listed six swiss exchange relief therapeutics founded gael h√©dou aim developing new treatments diseases high unmet company today considers successor mondobiotech founded fabio cavalli dorian mondobiotech began research vasoactive intestinal peptide vip naturally occurring substance humans first identified granted us european patents synthetic version vip known aviptadil june mondobiotech merged italian pharmaceutical company pierrel research international form new contract research organization known therametrics july therametrics merged relief therapeutics form relief therapeutics holdings ag inherited patents related wake pandemic scientists relief conducted initial studies efficacy treating severe patients june us food drug administration granted fasttrack designation treatment respiratory distress september relief partnered usisraeli firm nrx pharmaceuticals formerly neurorx inc codevelopment drug coordination us april reformulated version aviptadil known zyesami included national institutes health nih sponsored phase trial aim testing aviptadil may nrx submitted request emergency use authorization eua us fda aviptadils use patients intensive october relief therapeutics filed lawsuit nrx pharmaceuticals ceo dr jonathan javitt supreme court state new citing multiple alleged breaches collaboration agreement signed two companies codevelopment november fda declined eua drug committed working nrx develop november nrx announced data analysis nihsponsored phase trial showed fourfold increase survival days patients administered zyesami aviptadil vs received october applied pharma research apr whollyowned subsidiary relief announced positive interim data clinical trial sentinox nasal spray aimed reducing viral load patients inturn reducing transmissibility october relief announced collaboration partner texasbased acer therapeutics successfully filed new drug application us fda drug treatment urea cycle disorders ucds maple syrup urine september apr launched chewable tablet treatment phenylketonuria called pku golike krunch germany apr also developing nexodyn drug aids management hardtoheal ulcers requiring long periods relief actively developing related acute chronic lung diseases pulmonary httpsenwikipediaorgwikirelieftherapeutics